FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009289218> ?p ?o ?g. }

• W3009289218 endingPage "153203" @default.
• W3009289218 startingPage "153203" @default.
• W3009289218 abstract "Sjogren's syndrome (SS) is an inflammatory autoimmune disease whose etiology is complicated. Total glucosides of paeony (TGP) has a variety of pharmacological effects. To evaluate the therapeutic effects of TGP on SS in mice and anti-inflammatory mechanism. SS animal model was developed from C57BL/6J mice through immunological induction (SS mice) and NOD/ShiltJNju (NOD) mice. Inflammatory cytokines and other related indicators were measured. TGP (720, 360, 180 mg/kg) was intragastrically administered for 6 or 16 weeks for SS mice and NOD mice, respectively. Average food and water intake, average body weight, saliva flow, submandibular gland (SMG) and spleen index, and SMG pathology were measured. ELISA was used to evaluate serum inflammatory cytokines in SS mice and autoantigens in NOD mice. Real-time PCR, Western blot and Luminex liquid suspension chip assay were applied to analyze SMG inflammatory cytokines mRNA and protein expression of NOD mice. Compared with SS mice, TGP treatment improved SMG pathological damage. TGP (720 mg/kg) treatment increased saliva flow, and reduced organ indexes and serum IL-6 and IFN-γ concentration. TGP (360 mg/kg) treatment decreased serum IFN-γ concentration. TGP (180 mg/kg) treatment for 6 weeks decreased average body weight. Compared with NOD mice, TGP treatment increased saliva flow from 9 to 15 weeks, decreased body weight, and alleviated pathological damage of SMG after 2 and 16 weeks. After 2 weeks of administration, TGP treatment inhibited serum concentration of SSB/La, SSA/Ro and α-fodrin, decreased TNF-α, IL-1β and IFN-γ in SMG, and down-regulated protein expressions of BAFF and IL-17A and mRNA expressions of BAFF, TNF-α, IL-17A, CXCL9 and CXCL13 in SMG. After 8 weeks of administration, TGP treatment decreased the concentration of α-fodrin in serum, TNF-α and IL-6 in SMG, and down-regulated mRNA expressions of IL-17A, TNF-α, CXCL9, CXCL13 and BAFF and protein expressions of IL-17A and BAFF in SMG. After 16 weeks of administration, TGP treatment reduced serum SSA/Ro, SSB/La and α-fodrin concentration, and decreased BAFF protein expression and TNF-α, CXCL9, CXCL13, IL-17A, and BAFF mRNA expressions. TGP has a certain therapeutic effect on SS mice and NOD mice through inhibiting inflammatory responses." @default.
• W3009289218 created "2020-03-13" @default.
• W3009289218 creator A5005043215 @default.
• W3009289218 creator A5007479656 @default.
• W3009289218 creator A5010092441 @default.
• W3009289218 creator A5010295861 @default.
• W3009289218 creator A5013437527 @default.
• W3009289218 creator A5022980110 @default.
• W3009289218 creator A5055218910 @default.
• W3009289218 creator A5058938740 @default.
• W3009289218 creator A5060987863 @default.
• W3009289218 creator A5064376545 @default.
• W3009289218 creator A5064627383 @default.
• W3009289218 date "2020-06-01" @default.
• W3009289218 modified "2023-10-16" @default.
• W3009289218 title "Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice" @default.
• W3009289218 cites W1968751414 @default.
• W3009289218 cites W2011127086 @default.
• W3009289218 cites W2029167801 @default.
• W3009289218 cites W2061353036 @default.
• W3009289218 cites W2080259979 @default.
• W3009289218 cites W2088300722 @default.
• W3009289218 cites W2113623657 @default.
• W3009289218 cites W2146003955 @default.
• W3009289218 cites W2171417936 @default.
• W3009289218 cites W2292432120 @default.
• W3009289218 cites W2412276861 @default.
• W3009289218 cites W2611162199 @default.
• W3009289218 cites W2739106063 @default.
• W3009289218 cites W2740588853 @default.
• W3009289218 cites W2775569725 @default.
• W3009289218 cites W2802431486 @default.
• W3009289218 cites W2903923292 @default.
• W3009289218 cites W4235790631 @default.
• W3009289218 doi "https://doi.org/10.1016/j.phymed.2020.153203" @default.
• W3009289218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32402913" @default.
• W3009289218 hasPublicationYear "2020" @default.
• W3009289218 type Work @default.
• W3009289218 sameAs 3009289218 @default.
• W3009289218 citedByCount "11" @default.
• W3009289218 countsByYear W30092892182020 @default.
• W3009289218 countsByYear W30092892182021 @default.
• W3009289218 countsByYear W30092892182022 @default.
• W3009289218 countsByYear W30092892182023 @default.
• W3009289218 crossrefType "journal-article" @default.
• W3009289218 hasAuthorship W3009289218A5005043215 @default.
• W3009289218 hasAuthorship W3009289218A5007479656 @default.
• W3009289218 hasAuthorship W3009289218A5010092441 @default.
• W3009289218 hasAuthorship W3009289218A5010295861 @default.
• W3009289218 hasAuthorship W3009289218A5013437527 @default.
• W3009289218 hasAuthorship W3009289218A5022980110 @default.
• W3009289218 hasAuthorship W3009289218A5055218910 @default.
• W3009289218 hasAuthorship W3009289218A5058938740 @default.
• W3009289218 hasAuthorship W3009289218A5060987863 @default.
• W3009289218 hasAuthorship W3009289218A5064376545 @default.
• W3009289218 hasAuthorship W3009289218A5064627383 @default.
• W3009289218 hasConcept C104317684 @default.
• W3009289218 hasConcept C126322002 @default.
• W3009289218 hasConcept C134018914 @default.
• W3009289218 hasConcept C164027704 @default.
• W3009289218 hasConcept C185592680 @default.
• W3009289218 hasConcept C203014093 @default.
• W3009289218 hasConcept C2776415932 @default.
• W3009289218 hasConcept C2776914184 @default.
• W3009289218 hasConcept C2778013207 @default.
• W3009289218 hasConcept C2780931953 @default.
• W3009289218 hasConcept C504460877 @default.
• W3009289218 hasConcept C55493867 @default.
• W3009289218 hasConcept C555293320 @default.
• W3009289218 hasConcept C55851684 @default.
• W3009289218 hasConcept C71924100 @default.
• W3009289218 hasConceptScore W3009289218C104317684 @default.
• W3009289218 hasConceptScore W3009289218C126322002 @default.
• W3009289218 hasConceptScore W3009289218C134018914 @default.
• W3009289218 hasConceptScore W3009289218C164027704 @default.
• W3009289218 hasConceptScore W3009289218C185592680 @default.
• W3009289218 hasConceptScore W3009289218C203014093 @default.
• W3009289218 hasConceptScore W3009289218C2776415932 @default.
• W3009289218 hasConceptScore W3009289218C2776914184 @default.
• W3009289218 hasConceptScore W3009289218C2778013207 @default.
• W3009289218 hasConceptScore W3009289218C2780931953 @default.
• W3009289218 hasConceptScore W3009289218C504460877 @default.
• W3009289218 hasConceptScore W3009289218C55493867 @default.
• W3009289218 hasConceptScore W3009289218C555293320 @default.
• W3009289218 hasConceptScore W3009289218C55851684 @default.
• W3009289218 hasConceptScore W3009289218C71924100 @default.
• W3009289218 hasFunder F4320321542 @default.
• W3009289218 hasFunder F4320335960 @default.
• W3009289218 hasLocation W30092892181 @default.
• W3009289218 hasLocation W30092892182 @default.
• W3009289218 hasOpenAccess W3009289218 @default.
• W3009289218 hasPrimaryLocation W30092892181 @default.
• W3009289218 hasRelatedWork W1992066058 @default.
• W3009289218 hasRelatedWork W2003034820 @default.
• W3009289218 hasRelatedWork W2043512289 @default.
• W3009289218 hasRelatedWork W2053067715 @default.
• W3009289218 hasRelatedWork W2088931082 @default.
• W3009289218 hasRelatedWork W2090580735 @default.

• next